Intensive Care Erasmus MC-Sophia Children's Hospital, Dr. Molewaterplein 60, 3000 CB Rotterdam, The Netherlands.
Curr Drug Metab. 2012 Jul;13(6):767-77. doi: 10.2174/138920012800840383.
ECMO support is an established life saving therapy for potentially reversible respiratory and/or cardiac failure. Improvement of outcome depends on effective treatment of the primary diagnosis and complications. Adequate drug therapy is important in reaching these goals. Pharmacokinetic and pharmacodynamic data in neonates and older children on ECMO are sparse. Most studies show altered volume of distribution and clearance for the drugs studied. This article gives an overview of the available PK and PD studies in neonates and children on ECMO, suggests possible mechanisms of altered PK and PD and identifies areas of interest for further research.
体外膜肺氧合（ECMO）支持是一种治疗潜在可逆转的呼吸和/或心功能衰竭的成熟救生疗法。改善预后取决于对主要诊断和并发症的有效治疗。适当的药物治疗对于实现这些目标很重要。在 ECMO 上的新生儿和大龄儿童的药代动力学和药效学数据很少。大多数研究表明，所研究药物的分布容积和清除率发生了改变。本文概述了 ECMO 上新生儿和儿童的可用药代动力学和药效学研究，提出了药代动力学和药效学改变的可能机制，并确定了进一步研究的兴趣领域。
